SHR-1918

Phase 3Small molecule

BBeijing Suncadia Pharmaceuticals Co., Ltd

SHR-1918 is one of 35 small molecule programs targeting Hypercholesterolemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypercholesterolemiaNot yet recruiting

HypertriglyceridemiaActive, not recruiting

Homozygous Familial HypercholesterolemiaCompleted

HypercholesterolemiaPhase 3

Not yet recruiting

HypertriglyceridemiaPhase 3

Active, not recruiting

Homozygous Familial HypercholesterolemiaPhase 3

Completed

Competition

Competitive Landscape

24 competitors in Hypercholesterolemia

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

17 2

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

31 3

Leqvio

Novartis

Approved

4 4

Zocor

OOrganon and Co

Approved

14 5

Livalo

MMedicure

Approved

6 6

Praluent

Regeneron

Phase 3

19 7

Lesinurad

EEsperion Therapeutics, Inc.

Approved

4 8

Niacor

Tricor

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Hypertriglyceridemia

NCT07349615

Phase 3Recruiting

Hyperlipidemia

NCT07230730

Phase 2Not yet recruiting

Homozygous Familial Hypercholesterolemia

NCT07133815

Q3 2028

Phase 2/3Not yet recruiting

Hypercholesterolemia

NCT07404553

Clinical

Trials by Indication[1]

Homozygous Familial Hypercholesterolemia3 trials

Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Not yet recruiting·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 2·NCT07133815·55 enrolled

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Completed·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 2·NCT06009393·26 enrolled

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Completed·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 3·NCT06723652·55 enrolled

Hypercholesterolemia1 trial

A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

Not yet recruiting·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 2/3·NCT07404553·126 enrolled

Efficacy and Safety1 trial

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

Completed·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 2·NCT06109831·335 enrolled

Hypertriglyceridemia1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypertriglyceridemia

Active, not recruiting·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 3·NCT07349615·367 enrolled

Hyperlipidemia1 trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

Recruiting·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 3·NCT07230730·900 enrolled

1 more indication

Unspecified1 trial

Safety and Tolerability of SHR-1918 in Healthy Subjects

Unknown status·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 1·NCT05432544·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for SHR-1918. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-1918 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-1918. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Suncadia Pharmaceuticals Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Suncadia Pharmaceuticals Co., Ltd

SHR-1918

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Trials by Indication[1]

Homozygous Familial Hypercholesterolemia3 trials

Hypercholesterolemia1 trial

Efficacy and Safety1 trial

Hypertriglyceridemia1 trial

Hyperlipidemia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News